Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.
Company profile
Ticker
ADIL, ADILW
Exchange
Website
CEO
William B. Stilley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adial Pharmaceuticals, L.L.C., ADial Pharmaceuticals, L.L.C.
SEC CIK
Corporate docs
Subsidiaries
Purnovate, Inc. ...
IRS number
800667150
ADIL stock data
Latest filings (excl ownership)
8-K
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
31 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 23
8-K
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
21 Mar 23
8-K
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
7 Mar 23
DEF 14A
Definitive proxy
6 Mar 23
D
$61.60 k in options / securities to be acquired, sold $61.60 k, 1 investor
6 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Mar 23
8-K
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
27 Feb 23
PRE 14A
Preliminary proxy
24 Feb 23
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.00 mm | 4.00 mm | 4.00 mm | 4.00 mm | 4.00 mm | 4.00 mm |
| Cash burn (monthly) | 583.62 k | 171.70 k | 1.08 mm | 1.11 mm | 583.62 k | 932.17 k |
| Cash used (since last report) | 1.76 mm | 518.38 k | 3.26 mm | 3.35 mm | 1.76 mm | 2.81 mm |
| Cash remaining | 2.24 mm | 3.48 mm | 741.14 k | 647.01 k | 2.24 mm | 1.19 mm |
| Runway (months of cash) | 3.8 | 20.3 | 0.7 | 0.6 | 3.8 | 1.3 |
Institutional ownership, Q4 2022
8.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 3 |
| Closed positions | 7 |
| Increased positions | 4 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 234.55 mm |
| Total shares | 2.30 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Schuyler Kevin | 673.60 k | $1.47 mm |
| Vanguard | 478.88 k | $102.96 mm |
| Renaissance Technologies | 251.89 k | $54.00 k |
| BLK Blackrock | 224.72 k | $48.32 mm |
| Geode Capital Management | 137.46 k | $29.00 k |
| Susquehanna International | 91.00 k | $19.38 mm |
| Virtu Financial | 87.41 k | $19.00 k |
| Two Sigma Investments | 58.39 k | $12.55 mm |
| STT State Street | 52.35 k | $11.15 mm |
| Commonwealth Equity Services | 36.46 k | $7.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Dec 22 | Stilley William B. III | Common Stock | Sale back to company | Dispose D | No | No | 0 | 166,667 | 0.00 | 1,020,979 |
| 20 Sep 22 | Cary J Claiborne | Common Stock | Grant | Acquire A | No | No | 0.4202 | 75,000 | 31.52 k | 1,100,000 |
| 19 Sep 22 | Cary J Claiborne | Common Stock | Grant | Acquire A | No | No | 0.4294 | 25,000 | 10.74 k | 1,025,000 |
| 22 Aug 22 | Stilley William B. III | Stock Options Common Stock | Grant | Acquire A | No | No | 0.555 | 100,000 | 55.50 k | 100,000 |
| 18 Aug 22 | Cary J Claiborne | Common Stock | Grant | Acquire A | No | No | 0 | 1,000,000 | 0.00 | 1,000,000 |
| 27 Jun 22 | Tony Goodman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.23 | 25,000 | 30.75 k | 25,000 |
News
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results And Provides Business Update; As Of December 31, 2022, Cash And Cash Equivalents Were $4M
30 Mar 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Mar 23
Adial Pharmaceuticals Engages The Keswick Group To Advance Partnering Activities For The Clinical Development Of AD04 For Alcohol Use Disorder
21 Mar 23
Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
8 Mar 23
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
7 Mar 23
Press releases
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
30 Mar 23
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
6 Mar 23
Adial Pharmaceuticals Schedules Business Update Conference Call
2 Mar 23
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
24 Feb 23
Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
21 Feb 23